| abstract |
The present invention relates to a pharmaceutical composition containing a compound represented by the formula: (see formula I) wherein R is an aliphatic hydrocarbon group, an aromatic hydrocarbon group, a heterocyclic group, a group represented by the formula: -OR1 (wherein R1 is H or an aliphatic hydrocarbon group) or a group represented by the formula -N(R1b)(R1c) (wherein R1b is H or an aliphatic hydrocarbon group and R1c is H or an aliphatic hydrocarbon group), R0 is H or an aliphatic hydrocarbon group, or R and R0 in combination represent a bond, ring A1 is a cycloalkene optionally substituted by 1 to 4 substituents selected from (1) an aliphatic hydrocarbon group, (2) an aromatic hydrocarbon group, (3) a group represented by the formula: -OR1 (wherein R1 is as defined above) and (4) a halogen atom, Ar is an aromatic hydrocarbon group optionally having substituents, a group represented by the formula: (see formula II) represents a group represented by the formula: (see formula III) or (see formula IV), and n is an integer of 1 to 4, a salt thereof or a prodrug thereof, and a nonionic surfactant and/or a cyclodextrin derivative readily soluble in water, and a method for improving solubility, stability or coloring property of the compound, a salt thereof or a prodrug thereof. |